MA
LUNG icon

MCF Advisors’s Pulmonx LUNG Stock Holding History

MCF Advisors’s Portfolio LUNG Stock Details LUNG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-575
Closed -$10K – 856
2022
Q3 		$10K Buy
+575
New +$10.6K ﹤0.01% 552

Other funds holding LUNG

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

MCF Advisors's LUNG Position: Q4 2022 in Review

MCF Advisors sold out of Pulmonx (LUNG) in Q4 2022, closing a stake of 575 shares — an estimated $10K sold.

MCF Advisors first reported a position in LUNG in Q3 2022 and held it in 1 quarter. The position peaked at $10K in Q3 2022. 116 funds tracked by Wall St. Rank hold LUNG as of Q4 2022.

  • MCF Advisors reported no remaining Pulmonx position as of Q4 2022 after selling out during the quarter.
  • MCF Advisors sold 575 Pulmonx shares in Q4 2022, an estimated $10K.
  • MCF Advisors first reported a position in Pulmonx in Q3 2022 and held it in 1 quarter.
  • MCF Advisors's Pulmonx position peaked at $10K in Q3 2022.
  • 116 funds tracked by Wall St. Rank held Pulmonx as of Q4 2022.

Based on MCF Advisors's 13F filing for Q4 2022, filed 31 Jan 2023.